A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

NCT02439957 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated early due to results from another CMX001 study.

Conditions

Cytomegalovirus Disease
Kidney Transplant Infection

Interventions

DRUG: Brincidofovir
DRUG: Valganciclovir

Sponsor

Jazz Pharmaceuticals